ArticlePloS one2018
Human Borrelia miyamotoi infection in California: Serodiagnosis is complicated by multiple endemic Borrelia species.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Tick borne relapsing fever - a systematic review and analysis of the literature.PLoS neglected tropical diseases · 2022Pooled it
- Evidence of zoonotic rickettsiae in ixodid ticks of domestic animals in some communal farms in the Eastern Cape Province, South Africa.Journal of advanced veterinary and animal research · 2024Article
- A serological assay to detect and differentiate rodent exposure to soft tick and hard tick relapsing fever infections in the United States.Ticks and tick-borne diseases · 2023Article
- Borrelia miyamotoi Infection in Immunocompromised Man, California, USA, 2021.Emerging infectious diseases · 2023Article
- HumanPathogens (Basel, Switzerland) · 2023Review
- A comparison of horizontal and transovarial transmission efficiency of Borrelia miyamotoi by Ixodes scapularis.Ticks and tick-borne diseases · 2022Article
- Article
- Characterization of Immunological Responses toMicrobiology spectrum · 2022Article
- Modeling future climate suitability for the western blacklegged tick, Ixodes pacificus, in California with an emphasis on land access and ownership.Ticks and tick-borne diseases · 2021Article
- Simultaneous Detection and Differentiation of Clinically Relevant Relapsing FeverJournal of clinical microbiology · 2021Article
- Examining Prevalence and Diversity of Tick-Borne Pathogens in Questing Ixodes pacificus Ticks in California.Applied and environmental microbiology · 2021Article
- Review
- Borrelia miyamotoi strain LB-2001 retains plasmids and infectious phenotype throughout continuous culture passages as evaluated by multiplex PCR.Ticks and tick-borne diseases · 2021Article
- Pathogenesis of Relapsing Fever.Current issues in molecular biology · 2021Review
- Characterization of a Borrelia miyamotoi membrane antigen (BmaA) for serodiagnosis of Borrelia miyamotoi disease.Ticks and tick-borne diseases · 2020Article
- Lyme Disease: Diversity ofHealthcare (Basel, Switzerland) · 2020Article
- Emerging Tick-Borne Diseases.Clinical microbiology reviews · 2020Review
- Article
- Immunoserological Diagnosis of Human Borrelioses: Current Knowledge and Perspectives.Frontiers in cellular and infection microbiology · 2020Review
- Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
To determine whether human Borrelia miyamotoi infection occurs in the far-western United States, we tested archived sera from northwestern California residents for antibodies to this emerging relapsing fever spirochete. These residents frequently were exposed to I. pacificus ticks in a region where B. miyamotoi tick infection has been reported. We used a two-step B. miyamotoi rGlpQ assay and a B. miyamotoi whole-cell lysate (WCL) assay to detect B. miyamotoi antibody. We also employed Borrelia hermsii and Borrelia burgdorferi WCL assays to examine if these Borrelia induce cross reacting antibody to B. miyamotoi. Sera were collected from 101 residents in each of two consecutive years. The sera of 12 and 14 residents in years one and two, respectively, were B. miyamotoi rGlpQ seroreactive. Sufficient sera were available to test 15 of the 26 seropositive samples using B. miyamotoi and B. hermsii WCL assays. Two residents in year one and seven residents in year two were seroreactive to both Borrelia antigens. Although discernible differences in seroreactivity were evident between the B. miyamotoi and B. hermsii WCL assays, infection with one or the other could not be determined with certainty. Sera from two Borrelia burgdorferi /B. miyamotoi seropositive subjects reacted strongly against B. miyamotoi and B. hermsii WCL antigens. Ecological, epidemiological, and clinical data implicated B. miyamotoi as the probable cause of infection among those whose sera reacted against both antigens. Our findings suggest that human B. miyamotoi infection occurs in northern California and that B. hermsii and B. burgdorferi infections produce antibodies that cross-react with B. miyamotoi antigens. Health care professionals in the far-western United States should be aware that B. miyamotoi disease may occur throughout the geographic distribution of I. pacificus and that improved relapsing fever group spirochete antibody assays are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.